At ESMO Congress 2026, joint teams presented results at from implementation of Paradigm Health’s platform to identify patients for clinical trial participation.
COLUMBUS, Ohio and MADRID — October 25, 2026 — Paradigm Health today announced results from joint research with Fujitsu Japan Limited and Japan’s National Cancer Center East (NCCE), presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid. The poster, titled, “Reasoning LLMs with structured EHR data and for scalable, cross-national clinical trial eligibility screening” (poster 132P, abstract 6946), describes a retrospective evaluation of Paradigm Health’s clinical trial screening platform using Japanese electronic health records from NCCE. The research tested how a U.S.-developed agentic platform could identify and organize potential trial candidates and evidence for physician review in Japan.
Oncology trial recruitment requires clinical teams to interpret diagnoses, disease stage, prior treatment, and genomic test results against trial-specific criteria. In this single-center study, Japanese electronic health records were translated into English and converted into structured key-value FHIR format by LLMs. Independent validation checks were performed on the machine translation. The U.S.-developed platform, hosted entirely in Japan, used a reasoning language model with fixed prompts to return criterion-level assessments, cited evidence, and temporal context.
In an expanded cohort of 3,027 patients with lung cancer, the research team evaluated the platform’s performance in addressing two distinct challenges in clinical trial screening: 1) finding potential candidates for trials targeting rare gene fusions, including those with unclear testing histories or results, and 2) reducing the research team’s chart-review burden for a much larger group of patients with EGFR-related findings. The analysis combined Japanese electronic health record data extracted and structured by Fujitsu Japan with Paradigm Health’s trial matching platform.
For a trial of a novel therapy targeting a rare RET fusion, the platform identified patients with either previously documented positive molecular results, or patients whose clinical presentation indicated likely trial eligibility and the need for confirmatory molecular testing. Of clinical importance, the platform identified 35 patients who were potentially trial eligible, but had not received RET fusion testing; after research team review, all 35 patients were deemed a priority for clinical review and follow-up testing. This approach is useful for clinical teams to identify potential candidates who may be eligible for rare molecularly-targeted trials but whose molecular profiling status requires confirmation.
Among 540 patients with EGFR-related findings, the platform identified 57 patients for oncologist review for trial eligibility. Oncologist human review determined that 51 of those 57 patients (89.5%) were appropriate to prioritize. 0 of the 483 patients who were deprioritized by the platform were determined to be trial appropriate, after human oncologist review. These findings suggest that physicians in busy clinical settings can use the platform to assess potential trial candidates far more efficiently than with conventional screening methods, making better use of their limited time. Final trial eligibility remains a clinical decision.
“Our work with Fujitsu Japan and NCCE shows that Japanese clinical records can be prepared for use with Paradigm Health’s platform and presented to physicians for efficient review,” said Jonathan Hirsch, co-founder and Chief Strategy & Growth Officer at Paradigm Health, who is one of the Paradigm Health presenters. “The results are an encouraging step toward connecting trial planning and conduct across healthcare systems, while keeping clinicians responsible for eligibility decisions.”
Based on these early results, the parties aim to deploy this model in Japan to help research teams plan trials around their patient populations, find potential participants, and make the data easier for regulators to review, across a range of Japanese hospitals. The goal is to bring more trial opportunities to patients in Japan and help sponsors conduct global research more effectively, in order to solve Drug Loss.
Building a model for clinical trials across borders
This research with NCCE and Fujitsu shows how Paradigm Health’s platform can benefit patients beyond those in the United States. By leveraging AI-based software deployed to hospitals in Japan, sponsors and research sites can better assess whether a trial is feasible, identify patients for review more efficiently, and accelerate high-quality trial execution. Over time, the same connected approach could inform how trials are planned, conducted, and reviewed across healthcare systems in different countries.
The partners expect to use this research to refine the health system’s trial matching approach and explore broader use in Japan. For pharmaceutical and biotechnology companies planning global studies, the collaboration offers a model to include more Japanese research sites and patients in clinical trials.
About Paradigm Health
Paradigm Health has engineered an AI-powered platform to make clinical trials more accessible and efficient, so that patients, researchers, and study sponsors can maximize the impact of clinical research. Incubated by ARCH Venture Partners and backed by leading healthcare and life sciences investors, Paradigm Health aims to break down barriers across the trial ecosystem through one seamless infrastructure implemented at healthcare provider organizations.
For more information, visit https://www.paradigmhealth.ai.
